University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)
1
presentation
0
follower
7
more
presentations
in this session
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.